person
as of 2026-07-01F. Markus Leweke, MD
at a glance
Roles: Principal Investigator, Study Director, Author
KOL signal score 9
1 publications · 1 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
University of Cologne
Roles
Principal Investigator, Study Director, Author
KOL signal
9
Publications
1 (1 high-value)
Trial investigator
yes
Publishes on
1 drugs
Trials led
5
Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia
NCT00637234Phase 2, Phase 3Completed
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients
NCT02088060Phase 2Terminated
A Clinical Trial on the Antipsychotic Properties of Cannabidiol
NCT00309413Phase 2Completed
Enhancing Recovery in Early Schizophrenia
NCT02926859Phase 2Active Not Recruiting
Evaluation Study of New Compounds With Potential Use in Schizophrenia
NCT00916201Phase 1Withdrawn
Publications & congress
1
Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol.
Psychiatry research · 2024 · high-value
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
drug
STUDY_DIRECTOR
PRINCIPAL_INVESTIGATOR